Clinicopathological characteristics and prognosis of pulmonary pleomorphic carcinoma: a population-based retrospective study using SEER data
Clinicopathological characteristics and prognosis of pulmonary pleomorphic carcinoma: a population-based retrospective study using SEER data
复制标题
DOI：
10.21037/jtd.2018.06.71
复制
发表时间：
2018-07-01
影响因子：
2.5
通讯作者：
Wang, Qun
中科院分区：
文献类型：
--
作者：
Yin, Jiacheng;Yang, Yong;Wang, Qun
背景：肺多形性癌（PPC）是一种罕见的恶性肿瘤。独特的临床病理特征和预后尚未描述。方法：提取、评估2004年至2014年间在监测、流行病学和最终结果（SEER）数据库中收集的PPC患者信息，并与NSCLC患者数据进行比较。总生存期（OS）通过Kaplan-Meier法进行评估。通过 Cox 比例风险回归进行单变量分析 (UVA) 和多变量分析 (MVA)，确定了预测 OS 的危险因素，并将结果用于构建列线图来预测 PPC 患者的 1 年、3 年和 5 年 OS。 结果：在 320,510 名 NSCLC 患者的记录中，总共确定了 309 名诊断为 PPC 的患者。中位年龄为 66（IQR，57-75）岁，59.2% 为男性，79.3% 为白人，63.9% 患有上叶肿瘤，77.0% 为低分化，38.0% 为 AJCC IV 期。中位 OS 为 9 (95% Cl: 6.69-11.31) 个月，5 年 OS 为 25.1% (95% Cl: 23.6-26.6%)。 PPC 患者的肿瘤明显较大且分化程度较低，根治性手术切除率较高，N+ 疾病较少，远处转移较少（P
Background: Pulmonary pleomorphic carcinoma (PPC) is a rare malignancy; unique clinicopathological characteristics and prognosis have not been described.Methods: PPC patient information collected in the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2014 were extracted, evaluated, and compared with NSCLC patient data. Overall survival (OS) was evaluated by the Kaplan-Meier method. Univariate analysis (UVA) and multivariate analysis (MVA) by the Cox proportional hazards regression identified risk factors that predicted OS and the results were used to construct a nomogram to predict 1-, 3-, and 5-year OS in PPC patients.Results: A total of 309 patients diagnosed with PPC were identified among the records of 320,510 NSCLC patients. The median age was 66 (IQR, 57-75) years, 59.2% were men, 79.3% were White, 63.9% had upper lobe tumors, 77.0% were poorly differentiated, and 38.0% were AJCC stage IV. Median OS was 9 (95% Cl: 6.69-11.31) months and 5-year OS was 25.1 % (95% Cl: 23.6-26.6%). PPC patients had significantly larger and less differentiated tumors, a higher rate of radical surgical resection, less N+ disease, and fewer distant metastases (P